부산대학교 도서관

The immunogenicity of recombinant adenoviruses (Ad) constitutes a major concern for their use in gene therapy. Antibody- and cell-mediated immune responses triggered by adenoviral vectors hamper long-term transgene expression and efficient viral readministration. We previously reported that interleukin (IL)-6 and tumor necrosis factor (TNF)-α play an essential role in both the acute phase and antibody response against Ad, respectively. As TNF-α controls the immune response and the development of the immune system, we examined here the consequence of blockade of TNF-α activity through Ad-mediated gene delivery of a dimeric mouse TNFR1-IgG fusion protein on transgene expression from a second Ad. Ad encoding TNFR1-IgG (AdTNFR1-Ig) was injected intravenously along with Ad encoding β-galactosidase or α1-antitrypsin transgene in wild-type (IL-6) but also in IL-6-deficient mice (IL-6) to analyze how TNF-α and IL-6 diminish liver gene transfer efficacy. Blockade of TNF-α leads to increased transgene expression in both wild-type and IL-6 mice due to a reduced inflammatory response and to diminished recruitment of macrophages and NK cells towards the liver. Antibody responses against adenoviral particles and expressed transgenes were only delayed in AdTNFR1-Ig-treated wild-type mice, but were markedly reduced in AdTNFR1-Ig-treated IL-6 mice. Finally, treatment of mice with etanercept, a clinically approved anti-TNF-α drug, confirmed the importance of controlling proinflammatory cytokines during gene therapy by adenoviral vectors.